A PHASE 2, RANDOMIZED, 24-WEEK, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF-OF-CONCEPT STUDY TO INVESTIGATE EFFICACY AND SAFETY OF LY4005130 IN ADULT PARTICIPANTS WITH NON-SEGMENTAL VITILIGO
- Registry ID
- J5D-MC-FPAD
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- ELI LILLY CANADA INC
- Start date
- 2026-05-26
- Last update
- 2026-04-14
Conditions
Related clinical trials
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING PHASE IIB STUDY TO ASSESS THE EFFICACY AND SAFETY OF GIA632 IN ADULT PARTICIPANTS WITH NON-SEGMENTAL VITILIGO FOLLOWED BY AN EXTENSION PERIOD
- A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RANGING TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ZASOCITINIB IN PARTICIPANTS WITH NONSEGMENTAL VITILIGO
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, SAFETY, AND EFFICACY STUDY OF RUXOLITINIB
CREAM IN PEDIATRIC PARTICIPANTS WITH NONSEGMENTAL VITILIGO
- A RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED PHASE 2B TRIAL EVALUATING THE EFFICACY, SAFETY & PHARMACOKINETICS OF VYN201 GEL IN THE TREATMENT OF NON-SEGMENTAL VITILIGO
- A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF UPADACITINIB IN ADULT AND ADOLESCENT SUBJECTS WITH NON-SEGMENTAL VITILIGO WHO ARE ELIGIBLE FOR SYSTEMIC THERAPY
- A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TITRATION, MULTI-CENTER EXTENSION STUDY
INVESTIGATING THE SAFETY, EFFICACY, AND TOLERABILITY OF RITLECITINIB (PF-06651600) IN ADULT AND ADOLESCENT PARTICIPANTS WITH
NONSEGMENTAL VITILIGO
View on source registry